There are many types of arthritis (rheumatoid, degenerative, post-traumatic, auto-immune induced, etc). The most common form is osteoarthritis. It is also known as degenerative joint disease (DJD). While the exact cause is unknown, there are known to be several possible causes including: injury, age, congenital predisposition and obesity. It is characterized by the breakdown of the articular cartilage within the joint.

Articular cartilage is a firm rubbery protein material covering the end of a bone. It acts as a cushion or shock absorber between the bones. When articular cartilage breaks down, this cushion is lost, and the bones will grind together. This causes the development of symptoms such as pain, swelling, bone spur formation and decreased motion. Osteoarthritis commonly affects weight bearing joints such as the knee, but it may affect any joint.

TREATMENT USING HYALGAN

Hyalgan, administered by injection for the relief of pain from osteoarthritis of the knee, is the first therapy of its kind in America.

It received clearance for marketing in May of 1997 from the U.S. Food and Drug Administration (FDA) for the treatment of pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics, e.g. acetaminophen.

Osteoarthritis is a degenerative joint disease that affects more than 15 million patients in America according to the Arthritis Foundation. While the origin of the disease is not known, the onset is usually gradual and is often localized in one or a few joints.

Hyalgan represents a new therapeutic approach in the treatment of osteoarthritis of the knee. Hyalgan is a preparation of highly purified sodium hyaluronate. Sodium hyaluronate is a chemical normally found in the body and present in high amounts in joints and in synovial fluid (which is contained in a joint). The body's own hyaluronate plays a number of key roles in normal joint function. In osteoarthritis, the quality and quantity of hyaluronate in the joint fluid and tissue may be deficient.

The Hyalgan injections replace or supplement the body's natural hyaluronic acid that is broken down by inflammation of the knee joint. The injections coat the articular cartilage surface, and thus provides a possible prophylactic barrier for the articular cartilage.

The treatment consists of 5 injections, administered directly into the knee, over 5 weeks. The treatment will relieve pain in the majority of patients for 12 months without the safety concerns of nonsteroidal anti-inflammatory drug (NSAID) therapy.

THIS MATERIAL DOES NOT CONSTITUTE MEDICAL ADVICE. IT IS INTENDED FOR INFORMATIONAL PURPOSES ONLY. PLEASE CONSULT A PHYSICIAN FOR SPECIFIC TREATMENT RECOMMENDATIONS.

THE CENTER FOR ORTHOPAEDICS & SPORTS MEDICINE

1211 Johnson Ferry Rd
Marietta, GA 30068
770-565-0011
http://www.arthroscopy.com